Voyager Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alfred W. Sandrock Jr.
- Full Time Employees
- 172
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 75 Sidney Street Lexington MA United States of America 02139
- IPO Date
- Nov 11, 2015
- CIK
- 0001640266
- Website
- voyagertherapeutics.com
- Similar Companies
- Business
- Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company focused on developing genetic medicines to treat neurological diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Friedreich's ataxia; its TRACER AAV capsid discovery platform enables intravenous delivery across the blood-brain barrier, while its wholly-owned pipeline features the anti-tau antibody VY7523 in Phase I for Alzheimer's disease, tau silencing gene therapy VY1706 advancing toward IND in 2026, a novel APOE gene therapy for Alzheimer's disease, and the non-viral Voyager NeuroShuttle platform with an undisclosed program in early development; partnered programs include FXN and GBA1 gene therapies with Neurocrine Biosciences, TDP-43 small molecules with Transition Bio for ALS/FTD, and additional CNS gene therapies licensed to Novartis and Alexion/AstraZeneca. Founded in 2013 and headquartered in Lexington, Massachusetts, the company operates primarily in the United States with global collaboration partners. Recent developments include the addition of a fourth wholly-owned Alzheimer's program targeting APOE in 2025, a new collaboration with Transition Bio for small molecule development, Neurocrine triggering a $3 million milestone for a fourth gene therapy candidate with preclinical toxicology initiation and expected IND updates by year-end 2025, and Novartis returning rights to two discovery-stage programs while advancing Huntington's disease, spinal muscular atrophy, and an undisclosed target.
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Reports First Quarter 2026 Financial and Operating Results
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease
Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028
Voyager to Present at Upcoming Investor Conferences
Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO)
Elixir begins mobilisation for Lorelle-3 as spud nears
Tamboran appoints Todd Abbott as CEO effective January 15
Fineqia’s Matteo Greco discusses crypto market trends - ICYMI
Immunic targets MS market with Phase 3 data - ICYMI
Arizona Gold & Silver CEO discusses latest high-grade drill results from Philadelphia project - ICYMI
Aftermath Silver secures 100% of Berenguela project - ICYMI